Quantumzyme Clears OTC Markets Caveat Emptor Designation
July 24th, 2025 7:27 PM
By: Newsworthy Staff
Quantumzyme Corp. has successfully had the 'Caveat Emptor' designation removed by OTC Markets Group, marking a significant step towards regulatory compliance and enhanced corporate transparency.
Quantumzyme Corp. (OTC: QTZM), a biotechnology firm specializing in computational enzyme engineering, announced the removal of the 'Caveat Emptor' designation by OTC Markets Group. This change reflects the company's transition to a Current Information issuer with a Verified Profile, indicating full compliance with OTC Markets' OTCID disclosure framework.
The removal follows Quantumzyme's cooperation with OTC Markets and the adoption of improved disclosure practices, including updated financial reports and corporate transparency measures. Naveen Kulkarni, CEO of Quantumzyme, emphasized the company's commitment to transparency, compliance, and market integrity as key priorities moving forward.
With the designation lifted, Quantumzyme aims to refocus on its business strategy and enhancing shareholder value. The company also reiterated its non-involvement in unauthorized promotional activities from March 2025, condemning such actions and affirming its cooperation with related inquiries.
Source Statement
This news article relied primarily on a press release disributed by NewMediaWire. You can read the source press release here,
